NCT01515956
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This open-label Phase 2 study will evaluate the safety and efficacy of weekly 2.0 mg/kg/wk infusions of BMN 110 in pediatric patients, less than 5 years of age at the time of administration of the first dose of study drug, diagnosed with MPS IVA (Morquio A Syndrome) for up to 208 weeks.
All
Up to 5 Years
No
BMN 110
Phase 2
Interventional
15
2011-10
2017-08-10
Oakland, California, United States
Manhasset, New York, United States
Monza, , Italy
Taipei, , Taiwan
Central Manchester, , United Kingdom
*required fields
"*" indicates required fields